DE69417397D1 - Lösung, die igf-1 enthält - Google Patents

Lösung, die igf-1 enthält

Info

Publication number
DE69417397D1
DE69417397D1 DE69417397T DE69417397T DE69417397D1 DE 69417397 D1 DE69417397 D1 DE 69417397D1 DE 69417397 T DE69417397 T DE 69417397T DE 69417397 T DE69417397 T DE 69417397T DE 69417397 D1 DE69417397 D1 DE 69417397D1
Authority
DE
Germany
Prior art keywords
igf
pct
mmol
formulation
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69417397T
Other languages
English (en)
Other versions
DE69417397T2 (de
Inventor
Ebba Florin-Robertsson
Jonas Fransson
Diane Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Publication of DE69417397D1 publication Critical patent/DE69417397D1/de
Application granted granted Critical
Publication of DE69417397T2 publication Critical patent/DE69417397T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69417397T 1993-01-15 1994-01-10 Lösung, die igf-1 enthält Expired - Fee Related DE69417397T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9300105A SE9300105D0 (sv) 1993-01-15 1993-01-15 Stable protein solution
PCT/SE1994/000010 WO1994015584A1 (en) 1993-01-15 1994-01-10 Solution containing igf-1

Publications (2)

Publication Number Publication Date
DE69417397D1 true DE69417397D1 (de) 1999-04-29
DE69417397T2 DE69417397T2 (de) 1999-09-09

Family

ID=20388550

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69417397T Expired - Fee Related DE69417397T2 (de) 1993-01-15 1994-01-10 Lösung, die igf-1 enthält

Country Status (12)

Country Link
US (1) US5783559A (de)
EP (1) EP0679079B1 (de)
JP (1) JP3580816B2 (de)
AT (1) ATE177942T1 (de)
AU (1) AU676882B2 (de)
DE (1) DE69417397T2 (de)
DK (1) DK0679079T3 (de)
ES (1) ES2131673T3 (de)
GR (1) GR3030383T3 (de)
NZ (1) NZ259951A (de)
SE (1) SE9300105D0 (de)
WO (1) WO1994015584A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
HU230275B1 (hu) * 1996-09-13 2015-11-30 Shire Human Genetic Therapies, Inc Eljárás tisztított humán alfa-galaktozidáz-A készítmények előállítására, és a tisztított készítményeket tartalmazó gyógyászati készítmények, alfa-gal-A-deficienciából eredő rendellenességek kezelésében történő alkalmazásra
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
JP2001522814A (ja) * 1997-11-07 2001-11-20 カイロン コーポレイション 増大されたigf−i溶解性を提供する組成物
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
UY25790A1 (es) * 1998-11-06 2000-08-21 Bio Sidus S A Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
BR0306685A (pt) 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Composição farmacêutica contendo grelina
CA2576473C (en) * 2004-08-24 2015-06-30 Daiichi Asubio Pharma Co., Ltd. Liquid preparation of physiologically active peptide
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CN112566652A (zh) 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke

Also Published As

Publication number Publication date
ES2131673T3 (es) 1999-08-01
DE69417397T2 (de) 1999-09-09
DK0679079T3 (da) 1999-10-11
EP0679079B1 (de) 1999-03-24
SE9300105D0 (sv) 1993-01-15
WO1994015584A1 (en) 1994-07-21
AU676882B2 (en) 1997-03-27
JP3580816B2 (ja) 2004-10-27
ATE177942T1 (de) 1999-04-15
GR3030383T3 (en) 1999-09-30
US5783559A (en) 1998-07-21
NZ259951A (en) 1996-10-28
JPH08505617A (ja) 1996-06-18
AU5893994A (en) 1994-08-15
EP0679079A1 (de) 1995-11-02

Similar Documents

Publication Publication Date Title
ATE177942T1 (de) Lösung, die igf-1 enthält
PT998288E (pt) Composicoes contendo capsaicina ou analogos de capsaicina e um anestesico local
ATE322283T1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
DE69630918D1 (de) Matrix für Iontophorese
NO972128L (no) 2,2-dikloralkankarboksylsyrer, fremgangsmåte for fremstilling av disse, legemiddel inneholdende disse og anvendelse derav for behandling av insulinresistens
Nanninga et al. Role of magnesium and calcium in the first and second contraction of glycerin-extracted muscle fibers
BR9506840A (pt) Preparação farmacêutica contendo ativadores de plasminogênio
DE69522702D1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE192656T1 (de) Verfahren zur behandlung von patienten mit chronischer lebererkrankung
CA2153787A1 (en) Solution containing igf-1
DK1019037T3 (da) Lægemiddel indeholdende delta-aminolevulinsyre
JP2001187750A (ja) 感染部位検知方法、それに使用する組成物およびその組成物の製造方法
Kozlov The effect of carbon dioxide gas on the content of ammonia, glutamine, and urea in the blood of amimals after injection of solutions of ammonium chloride
SU1769419A1 (ru) Способ лечения себорейного облысения
BG94567A (en) Medicaments for the treatment of aids and method for its application
UA43413C2 (uk) Спосіб одержання ін'єкційного засобу "ерихрозид" для лікування серцево-судинних захворювань
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
UA27060C2 (uk) Спосіб стимулюваhhя зовhішhьої секреції підшлуhкової залози
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
UA37377A (uk) Спосіб отримання мазі для лікування захворювань, які викликані внутрішньоклітинними інфекційними агентами
UA29106A (uk) Спосіб лікування вібраційної хвороби
RU94007471A (ru) Способ лечения мастопатии

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee